Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma

Area of Science:

• Oncology
• Surgical Pathology
• Endocrinology

Background:

• Thyroid cancer staging systems have undergone substantial revisions since 1968.
• The Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) have jointly developed staging criteria.
• Evolution of staging impacts diagnosis, treatment, and prognosis for well-differentiated thyroid cancer (WDTC).

Purpose of the Study:

• To comprehensively review the evolution of WDTC staging across eight published editions.
• To identify key changes and their justifications in thyroid cancer classification.
• To analyze the impact of staging revisions on patient management and outcomes.

Main Methods:

• Systematic review of eight editions of UICC and AJCC thyroid cancer staging systems.
• Analysis of changes in tumor size criteria, extrathyroidal extension, and age parameters.
• Comparative assessment of staging criteria across different publication years.

Main Results:

• Tumor size criteria reduced from 4 cm to under 1 cm, defining "microcarcinomas."
• Extrathyroidal extension became a key prognostic factor after the third edition.
• The age threshold for staging was raised from 45 to 55 years in the eighth edition, offering a more optimistic outlook for younger patients.

Conclusions:

• Thyroid cancer staging has become more refined, leading to safer and less invasive treatments.
• Updated staging improves survival rates and patient safety.
• The evolution reflects a deeper understanding of WDTC biology and patient stratification.